Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

A tumour cell population responsible for resistance to therapy and tumour relapse

Resistance to therapy is a major problem in cancer patients as the cells that resist to therapy is at the root of tumour relapse and is associated with high morbidity and mortality.

A better understanding of the mechanisms associated with resistance to therapy is essential for the development of better strategies to definitively eradicate cancer and prevent tumour relapse.

In a study published in Nature, researchers lead by Pr. Cédric Blanpain, MD/PhD, WELBIO investigator and Professor at the Université libre de Bruxelles, Belgium identified a population of tumour cells that persist following drug treatment, leading to cancer relapse following treatment discontinuation in basal cell carcinoma, the most frequent skin cancer.

The study also identifies a combination of drugs that can eliminate this the tumour population that resists to the therapy and prevents tumour relapse after treatment discontinuation.

Basal cell carcinoma is the most common human cancer, affecting several millions of new patients each year across the world. Vismodegib, a FDA approved drug is used for the treatment of locally advanced and metastatic basal cell carcinoma in humans.

Many patients treated with vismodegib experience tumour regression during treatment, but very often their tumours relapse following treatment discontinuation.

The precise mechanisms involved in tumour regression upon vismodegib administration and how the tumour cells resist to the therapy leading to cancer relapse are poorly understood.

In this new study, Adriana Sánchez-Danés - Université libre de Bruxelles, ULB, Laboratory of Stem Cells and Cancer - and colleagues identified the mechanism by which vismodegib leads to tumor regression and uncovered the origin of the relapse observed upon treatment discontinuation.

They found that vismodegib promotes the differentiation of the bulk of tumour cells, leading to their elimination.

Vismodegib treatment led to the emergence of population of dormant tumour cells characterised by active Wnt signaling that persists despite continuous drug administration.

In collaboration with the groups of Pr. Tabernero (Barcelona, Spain) and Pr. del Marmol (Brussels, Belgium), the researchers demonstrated that this population of tumour cell population active for Wnt signaling was also found in patients with basal cell carcinoma treated with vismodegib.

Adriana Sánchez-Danés and colleagues found that inhibition of Wnt signaling together with Vismodegib eliminates the persisting tumour lesions leading to tumour eradication in the vast majority of the cases.

"It was really exciting to identify a combination of drugs already available in clinics that lead to the eradication of resisting tumour cells and avoiding tumour relapse in the most frequent cancer in humans", comments Adriana Sánchez-Danés, the first author of the study.

Altogether, this study illustrates that vismodegib promotes tumour regression by promoting the differentiation of tumour cells.

This demonstrates for the first time that inducing tumour differentiation is a safe and efficient strategy to treat solid tumours such as basal cell carcinoma.

This is the first example of a FDA approved drug used to treat solid tumour that induces tumour regression through differentiation.

"Tumour differentiation is an exciting route to treat cancer as it is non toxic for normal cells and was proved to be a revolutionary treatment in certain Leukaemia" said Cédric Blanpain, the senior author of study.

"Our study also identifies a new mechanism of resistance to therapy in basal cell carcinoma and demonstrates that the administration of two existing drugs is sufficient to prevent tumour relapse in the vast majority of the cases. The next step would be to conduct clinical trials using the combination of these two drugs in patients with relapsing basal cell carcinomas and possibly other cancers characterised by the activation of the two signalling pathways identified here", explains Cédric Blanpain, the corresponding author of the Nature paper.

Source: Homepage de l'Université libre de Bruxelles

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation